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A Prospective Trial of Minimal Intensity Conditioning
with Fludarabine and Anti-CD52 Antibody Alone in
Dyskeratosis Congenita
Leslie E. Lehmann 1,2, David A. Williams 1,2,
Wendy B. London 1,2, Suneet Agarwal 1,2. 1 Pediatric Oncology,
Dana-Farber Cancer Institute, Boston, MA; 2Hematology/
Oncology, Boston Children’s Hospital, Boston, MA
Background: Dyskeratosis congenita (DC) is an inherited
bone marrow failure (BMF) syndrome classically present-
ing with a clinical triad of skin pigment abnormalities, nail
dystrophy, and oral leukoplakia. Progressive BMF occurs in
approximately 80% of patients by 30 years of age and is
the primary cause of death, followed by pulmonary failure
and malignancies. HCT for DC is limited by a high inci-
dence of treatment-related mortality, due to the exacer-
bation of underlying multi-organ disease by alkylating
agents and radiation in the conditioning regimen. DC is
caused by lesions in telomere biology genes, which
compromise cellular replicative capacity. Because of this
intrinsic cellular defect, we hypothesize that DC patients
will show acceptable rates of engraftment with a mini-
mally cytotoxic conditioning regimen that excludes
alkylating agents and radiation. Vuong et al. (Acta Hema-
tologica, 2010) have previously reported successful
engraftment in a single DC patient using ﬂudarabine and
antithymocyte globulin conditioning. Based on this ratio-
nale and experience, we initiated a prospective HCT trial
with immunosuppression-only conditioning, which would
be predicted to improve outcomes and reduce secondary
malignancies in DC patients.
Methods: Patients up to age 30 years old with a well-
matched bone marrow donor are conditioned with anti-
CD52 and ﬂudarabine, and receive cyclosporine A and
mycophenolate mofetil as graft versus host disease (GVHD)
prophylaxis. Primary outcome measures include neutrophil
engraftment at day +30 and survival at day +100, and
secondary outcome measures include rates of graft failure,
infections, GVHD, secondary malignancies, and acute and
long-term toxicities.
Results: 3 patients with DC underwent unrelated donor
HCT with one-year follow-up. 18 month-old identical
twins with TINF2 mutations and transfusion-dependent
BMF received HCT from a fully HLA-matched donor, and
were plateleteindependent and neutrophil engrafted by
day +28. Myeloid chimerism was consistently fully donor.
Lymphoid chimerism was <10% donor on day +100, and
increased to 88-95% donor by one year post-transplant.
The third patient was an 18 year-old female with DC due
to CTC1 mutations and transfusion-dependent BMF,
who underwent single allele (HLA B) mismatched HCT.
She was platelet-independent and neutrophil-engrafted
by day +21. Myeloid and lymphoid chimerism were
fully donor in the post-transplant period. Currently one
year post-HCT, all three patients are transfusion-inde-
pendent and off immunosuppression without signiﬁcant
toxicities.
Conclusions: Early data suggest the feasibility of an immu-
nosuppression-only conditioning regimen for allogeneic HCT
in patients with DC. Ongoing studies will determine the
general applicability of this regimen in a disease as hetero-
geneous as DC, and longer-term follow-up will reveal the
impact on late effects.239
High-Dose Chemotherapy with Busulfex and Melphalan
As Conditioning Regimen Followed By Autologous STEM
CELL Rescue for Pediatric Patients with High-Risk
Neuroblastoma
Menachem Bitan, Maram Abu-yaman, Nitzan Cohen-Newman,
Ronit Elhasid. Pediatric Hematology/Oncology & BMT, Tel-Aviv
Sourasky Medical Center, Tel-Aviv, Israel
Introduction: High-dose chemotherapywith stemcell rescue
(auto-transplant) became a well established consolidation
procedure for high-risk neuroblastoma patients. We summa-
rize our cumulative experience using busulfex andmelphalan
rather than carboplatin/etoposide/melphalan as preparative
regimen for transplanting these pediatric patients.
Patients & Methods: Six pediatric patients aged 4-10 year
old (median 5.75 year old), 3 males and 3 females underwent
auto-transplant. All received busulfex 0.95-1.1mg/kg/dose,16
doses on days -7 to -3 andmelphalan 140mg/m2, one dose on
day -1. Busulfex levels were measured and appeared to range
between 981-1222mM per minute (median: 1136mM per
minute), with no correction needed (normal level range of
850-1400mM per minute). Cell reconstitution included total
nuclear cell (TNC) dose of 5.01-23.7x108/kg (median
15.2x108/kg) cells, and CD34+ cell content of 4.15-9.58x106/
kg (median 6.26x106/kg) cells.
Results: Conditioning was well tolerated. No patient devel-
oped veno-occlusive-disease (VOD) of the liver. Trilineage
engraftment was documented in all patients and none
exhibited graft failure. Time to recovery of absolute neutro-
phil count>0.5x109/L was 9 - 11 (median 9) days. The time to
platelet recovery >or¼20 and >or¼50x109/L ranged from 11
to 12 (median 12) days, and from 12 to 32 (median 22) days,
respectively. One patient did not achieve platelets count
above 20x109/L and another one did not achieve platelets
count above 50x109/L, before their discharge. Hospitalization
period ranged between 23-29 days (median: 26 days).
Moderate to severe mucositis was the major adverse event
post transplant, causing all patients to be supported by total
parental nutrition (TPN) for 7-12 days (median: 11 days).
Three patients suffered from culture-negative febrile neu-
tropenia and received antibiotics until neutrophil engraft-
ment. Transplant-related mortality did not occur in any of
the patients.
Conclusions: Busulfex and melphalan -based preparative
protocols arewell tolerated, facilitate rapid engraftment with
minimal toxicity, and may be considered for pediatric pa-
tients with high-risk neuroblastoma in need for auto-trans-
plant. Larger cohort of patients is needed to further conﬁrm
our results.240
Prevalence and Impact of Poverty in Pediatric Allogeneic
Hematopoetic Stem Cell Transplant
Kira Bona 1,2, Leslie E. Lehmann 1, Wendy B. London 2,
Joanne Wolfe 2,3. 1 Pediatric Oncology, Dana-Farber Cancer
Institute, Boston, MA; 2Hematology/Oncology, Boston
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Background: Despite emerging evidence of substantial
ﬁnancial distress in families of children with cancer, little is
known about the impact of economic hardship on pediatric
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is known to be correlated with negative health outcomes in
pediatric primary care and subspecialties; it is not known
how poverty impacts HSCT outcomes.
Objective: To describe the baseline prevalence of poverty
and material hardship in the pediatric HSCT population at a
major referral center. To describe transplant-related work
disruptions and income losses stratiﬁed by federal poverty
level (FPL) in this patient population, and explore the rela-
tionship between family poverty and clinical outcomes.
Methods: Single institution, cross-sectional survey. Partici-
pants included 45 English-speaking, pediatric allogeneic
HSCT families whose children had undergone HSCT in the
prior twelve months and were alive at time of survey
administration. Eighty-seven percent of families approached
consented to study participation. This studywas approved by
the Dana-Farber Cancer Institute Institutional Review Board.
Results: Poverty prior to transplant was prevalent with 18
(40%) families reporting baseline incomes at or below 200%
FPL ($44,000 for a family of four). Parental work disruptions
due to HSCT were common across all income levels with 39
(87%) families reporting some disruption, and consequent
income losses were substantial for all families. Families at or
below 200% FPL were disproportionately impacted with 7
(39%) of the poorest families reporting transplant-associated
annual income losses of >40% as compared to 2 (18%) of the
wealthiest families (p¼0.006). Material hardship during the
post-transplant period was widespread, with 17 (38%) fam-
ilies reporting either food, housing, or energy insecurity.
Baseline family poverty level was not associated with length
of transplant admission, unplanned re-admissions, or ICU
stay in the 6-month post-transplant period in univariate
analysis. Poorer children, however, were more likely to
experience Graft Versus Host Disease (GVHD) of any grade in
the 6 month post-transplant period with eleven (61%) of
those at or below 200% FPL experiencing GVHD as compared
with 2 (18%) of the wealthiest (p¼0.01).
Conclusion: Baseline poverty is widely prevalent in the pe-
diatric HSCT population, and poverty may be associated with
the development of GVHD. Material hardship during the
post-transplant perioddincluding food, housing, or energy
insecuritydis widespread. Further studies aimed at under-
standing how these social determinants of health contribute
to HSCToutcomesmay provide targetable factors to decrease
transplant-associated morbidity and mortality.241
Allogeneic Hematopoietic Stem Cell Transplantation
(HSCT) for Non Malignant Hematologic Disorders
(NMHD), Using a Chemotherapy-Only Cytoreductive
Regimen and T-Cell Depleted Grafts from Alternative
Donors
Farid Boulad, Nancy A. Kernan, Susan E. Prockop,
Andromachi Scaradavou, Rachel Lehrman,
Julianne M. Ruggiero, Kevin Curran, Rachel Kobos,
Richard O’Reilly. Department of Pediatrics, Bone Marrow
Transplant Service, Memorial Sloan-Kettering Cancer Center,
New York, NY
Non-malignant hematologic disorders of childhood
comprise a number of various disorders including acquired
severe aplastic anemia (SAA), and inherited marrow failure
syndromes. Patients with such diseases who do not have
matched related donors fare poorly with allogeneic HSCT
from alternative donors and are at high risk for developing
chronic GvHD.We report 14 patients aged 0.7-18 years of age
(median 5.3 years) who received T-cell depleted HSCT fromalternative donors between April 2005 and May 2013. Dis-
eases included acquired SAA including PNH (N¼6), severe
chronic neutropenia (SCN)(N¼2), congenital amegakar-
yotycic thrombocytopenia (N¼2), Shwachman Diamond
syndrome (N¼1), autoimmune hemolytic anemia (N¼1),
chronic granulomatous disease (N¼1) and hemophagocytic
lymphohistiocytosis (N¼1). Two patients with SAA had
constitutional abnormalities and were therefore thought to
have possibly genetic diseases despite negative testing for
deﬁned disorders. Ten patients had long standing symp-
tomatic disease for> 1 year prior to transplant. Patients with
Fanconi anemia and dyskeratosis congenita were treated
with reduced intensity regimens and were not included.
Patients received one of 3 myeloablative regimens: Busulfan
Melphalan and Fludarabine (N¼2), Cyclophosphamide Thio
Flu (N¼3) or Mel, Thio Flu (N¼9). Patients received rabbit
ATG pre-transplant and ﬁlgrastim post transplant to promote
engraftment. Donors were unrelated HLA-matched donors
(N¼5), unrelated HLA-mismatched donors (N¼6) or related
HLA-mismatched donors (N¼2), and related phenotypic
matched donor (N¼1). Grafts included soybean agglutinin
negative, E-rosette negative bone marrow grafts (N¼5),
Isolex CD34+ E-rosette- peripheral blood stem cell grafts
(N ¼ 4), or CliniMACS CD34+ PBSC grafts (N¼5).
All 13 evaluable patients engrafted. Neutrophil engraftment
occurred on day +12 and platelet engraftment to 20,000 on
day +20 post transplant. Four patients died frommulti-organ
failure and/or infection (three of whom had a duration of
their disease of 2-7 years). One patient with SAA fully
engrafted with donor cells developed a pancytopenia post
transplant with secondary MDS in donor cells; this patient is
alive. Excluding one patient who is too early post transplant
and with a median follow-up of 2 years, 8 of 13 patients are
alive (OS 61%). None of these patients has evidence of GvHD.
These results should encourage proceeding to transplant
with chemotherapy-only cytoreductive regimens and T-cell
depleted stem cell transplants from alternative donors for
patients with nonmalignant hematologic disorders earlier in
the course of their disease.242
Lymphopenia in Patients with Hemophagocytic
Lymphohistiocytosis: Are B Cells Suppressed in These
Patients?
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Background: Hemophagocytic Lymphohistiocytosis (HLH) is
an immune regulatory disorder requiring allogeneic he-
matopoietic stem cell transfusion (HSCT) for long-term sur-
vival. More importantly, it is imperative to initiate treatment
early as delays in treatment can be associated with signiﬁ-
cant mortality. Unfortunately, there can be signiﬁcant over-
lap of the HLH diagnostic criteria with other non-HLH
conditions, thereby considerably delaying diagnosis and
therapy for HLH. Hence, surrogate markers are needed to aid
in the diagnosis and prevent delays in initiating therapy in
this life threatening disorder. Hypogammaglobulinemia has
been a less commonly reported feature of HLH. It has been
reported in SAP deﬁcient patients +/- HLH. More recently, it
has been reported in a few patients with XIAP deﬁciency and
STXBP2 mutations in association with colitis. We have
observed B-cell lymphopenia as well as hypogammaglobu-
linemia in patients with HLH at our institution. However, the
